Notes
Notes : (1) Changes in Significant Subsidiaries during the Period under Review: (Changes in specified subsidiaries resulting in a change in the scope of consolidation). New: Excluded: . (2) Changes in Accounting Policies and Changes in Accounting Estimates Changes in accounting policies that are required under IFRS: Changes in accounting policies other than : Changes in accounting estimates: (3) Number of Shares Issued (Common Stock). Number of shares issued as of the end As of December As of December 47,462,943 shares 43,513,149 shares of the period (including treasury stock) 31, 2021 31, 2020. Number of treasury stock as of the end of As of December As of December 1,313 shares 1,223 shares the period 31, 2021 31, 2020. Average number of shares for the period As of December 46,924,021 shares As of December 43,437,352 shares 31, 2021 31, 2020. * This consolidated financial report is not subject to audit procedures by certified public accountants or an auditing firm. * Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items Forward-looking statements including earnings forecasts contained in this report are based on currently available information and management's assumptions and beliefs regarding uncertainties that may impact future earnings forecasts.
BC, a consolidated subsidiary of the Company, produced continued ®strong sales growth in China for Etuary and further expanded its sales force . BC made steady progress on clinical trials in China for both F351 Phase III for HBV- induced liver fibrosis (enrollment commenced in January 2022) and F573 Phase I (also started in January, 2022.
Download Notes
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: